Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) Vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

NCT06363994 is registered in ClinicalTrials.gov with InnoCare Pharma Inc. as lead sponsor.

NCT NCT06363994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06363994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) Vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma
Lead sponsor
InnoCare Pharma Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
May 29, 2024
Completion date
June 25, 2032
Enrollment
476 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma